Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
Patient-reported outcome
Psychometric
Respiratory syncytial virus
RiiQ™
Validation
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
24
01
2023
accepted:
18
05
2023
medline:
5
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
epublish
Résumé
The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the construct validity, reliability, and responsiveness of the RiiQ™ Respiratory and Systemic Symptoms Scale scores. Prospective data were analyzed from a total of 1795 participants, including from non-hospitalized patients with acute respiratory infection (ARI) and no coinfections enrolled in a Phase 2b RSV vaccine study (RSV-positive: n = 60; RSV-negative: n = 1615), and two observational studies of patients hospitalized with RSV (n = 20; n = 100). Descriptive statistics, confirmatory factor analysis (CFA), test-retest intraclass correlation coefficients (ICCs), construct validity correlations (between a clinician-assessed clinical questionnaire and the RiiQ™ symptoms scale), known-groups validity, and responsiveness (correlations of change scores) were evaluated. Mean patient age ranged from 66.5 to 71.5 years and the majority of patients were female. Initial assessments in the vaccine trial (ARI Day 1) were suggestive of less severe illness than in the observational studies with hospitalized patients. CFA loadings (> 0.40) supported summary scores. ICCs exceeding the recommended threshold of 0.70 supported test-retest reliability for Respiratory and Systemic Symptoms, except in the small observational study. At the scale level, correlations were moderate to strong (|r| ≥ 0.3) and positive between the Respiratory Symptoms Scale and the related clinical questionnaire scores, reflecting measurement of similar symptoms in support of convergent validity. Correlations with change in Patient Global Impression of Severity > 0.30 supported responsiveness. Psychometric tests applied to the RiiQ™ Symptoms scales provide evidence of its reliability, construct validity, discriminating ability, and responsiveness for use in clinical studies to assess the onset and severity of RSV symptoms.
Sections du résumé
BACKGROUND
The Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) is a patient-reported outcome measure designed to assess symptoms and impacts of respiratory syncytial virus (RSV) infection. This study evaluated the construct validity, reliability, and responsiveness of the RiiQ™ Respiratory and Systemic Symptoms Scale scores.
METHODS
Prospective data were analyzed from a total of 1795 participants, including from non-hospitalized patients with acute respiratory infection (ARI) and no coinfections enrolled in a Phase 2b RSV vaccine study (RSV-positive: n = 60; RSV-negative: n = 1615), and two observational studies of patients hospitalized with RSV (n = 20; n = 100). Descriptive statistics, confirmatory factor analysis (CFA), test-retest intraclass correlation coefficients (ICCs), construct validity correlations (between a clinician-assessed clinical questionnaire and the RiiQ™ symptoms scale), known-groups validity, and responsiveness (correlations of change scores) were evaluated.
RESULTS
Mean patient age ranged from 66.5 to 71.5 years and the majority of patients were female. Initial assessments in the vaccine trial (ARI Day 1) were suggestive of less severe illness than in the observational studies with hospitalized patients. CFA loadings (> 0.40) supported summary scores. ICCs exceeding the recommended threshold of 0.70 supported test-retest reliability for Respiratory and Systemic Symptoms, except in the small observational study. At the scale level, correlations were moderate to strong (|r| ≥ 0.3) and positive between the Respiratory Symptoms Scale and the related clinical questionnaire scores, reflecting measurement of similar symptoms in support of convergent validity. Correlations with change in Patient Global Impression of Severity > 0.30 supported responsiveness.
CONCLUSIONS
Psychometric tests applied to the RiiQ™ Symptoms scales provide evidence of its reliability, construct validity, discriminating ability, and responsiveness for use in clinical studies to assess the onset and severity of RSV symptoms.
Identifiants
pubmed: 37261682
doi: 10.1186/s41687-023-00593-9
pii: 10.1186/s41687-023-00593-9
pmc: PMC10235291
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2023. The Author(s).
Références
Clin Infect Dis. 2019 Jul 2;69(2):197-203
pubmed: 30452608
N Engl J Med. 2023 Feb 16;388(7):609-620
pubmed: 36791161
Influenza Other Respir Viruses. 2022 May;16(3):462-473
pubmed: 34981637
Qual Life Res. 2018 Jul;27(7):1695-1710
pubmed: 29464456
Qual Life Res. 2019 Apr;28(4):1029-1033
pubmed: 30547346
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Heart Lung Transplant. 2023 Feb 7;:
pubmed: 36964084
Influenza Other Respir Viruses. 2022 Jan;16(1):79-89
pubmed: 34472708
Value Health. 2020 Feb;23(2):227-235
pubmed: 32113628
Value Health. 2011 Jul-Aug;14(5):687-99
pubmed: 21839407
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
BMC Infect Dis. 2016 Jan 05;16:1
pubmed: 26729246
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Open Forum Infect Dis. 2021 Oct 05;8(11):ofab491
pubmed: 35559130
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
Psychol Bull. 1992 Jul;112(1):155-9
pubmed: 19565683